135 related articles for article (PubMed ID: 24172799)
21. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
[No Abstract] [Full Text] [Related]
22. Impact of renin-angiotensin-aldosterone system-blocking agents on the risk of contrast-induced acute kidney injury: a prospective study and meta-analysis.
Peng F; Su J; Lin J; Niu W
J Cardiovasc Pharmacol; 2015 Mar; 65(3):262-8. PubMed ID: 25502308
[TBL] [Abstract][Full Text] [Related]
23. Shall we stop or continue angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to using contrast agents?
Ganji MR
Iran J Kidney Dis; 2012 Nov; 6(6):397-400. PubMed ID: 23146974
[No Abstract] [Full Text] [Related]
24. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy.
Cirit M; Toprak O; Yesil M; Bayata S; Postaci N; Pupim L; Esi E
Nephron Clin Pract; 2006; 104(1):c20-7. PubMed ID: 16685140
[TBL] [Abstract][Full Text] [Related]
25. Renin-angiotensin system blockers increase risk of angio-oedema.
Volpe M; Tocci G
Evid Based Med; 2013 Dec; 18(6):e52. PubMed ID: 23635842
[No Abstract] [Full Text] [Related]
26. Is there any difference between angiotensin converting enzyme inhibitors and angiotensin receptor blockers for heart failure?
Rain C; Rada G
Medwave; 2015 Jul; 15 Suppl 1():e6177. PubMed ID: 26247213
[TBL] [Abstract][Full Text] [Related]
27. Renal safety and angiotensin II blockade medications in patients undergoing non-emergent coronary angiography: a randomized controlled study.
Wolak T; Aliev E; Rogachev B; Baumfeld Y; Cafri C; Abu-Shakra M; Novack V
Isr Med Assoc J; 2013 Nov; 15(11):682-7. PubMed ID: 24511648
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI;
Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin-Converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers.
Tazkarji B; Ganeshamoorthy A; Auten B
Am Fam Physician; 2015 Feb; 91(3):193-4. PubMed ID: 25822274
[No Abstract] [Full Text] [Related]
30. The relation between renin-angiotensin-aldosterone system blockade and contrast-induced nephropathy: an unresolved issue.
Balta S; Aparci M
Cardiology; 2015; 130(1):1-3. PubMed ID: 25428132
[No Abstract] [Full Text] [Related]
31. ACE inhibitors, angiotensin II receptor blockers and pregnancy: fetal renal impairment.
Prescrire Int; 2013 Oct; 22(142):243. PubMed ID: 24298590
[No Abstract] [Full Text] [Related]
32. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study.
Onuigbo MA; Onuigbo NT
Ren Fail; 2008; 30(1):67-72. PubMed ID: 18197546
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
Salvador GL; Marmentini VM; Cosmo WR; Junior EL
Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020
[TBL] [Abstract][Full Text] [Related]
34. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study.
Bajaj RR; Wald R; Hackam DG; Gomes T; Perl J; Juurlink DN; Manno M; Garg AX; Kitchlu A; Mamdani MM; Yan AT
Arch Intern Med; 2012 Apr; 172(7):591-3. PubMed ID: 22493468
[No Abstract] [Full Text] [Related]
35. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
Barbieri L; Verdoia M; Schaffer A; Cassetti E; Marino P; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):181-6. PubMed ID: 25315668
[TBL] [Abstract][Full Text] [Related]
36. Angioedema related to Angiotensin inhibitors.
Knecht SE; Dunn SP; Macaulay TE
J Pharm Pract; 2014 Oct; 27(5):461-5. PubMed ID: 25124378
[TBL] [Abstract][Full Text] [Related]
37. Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors.
Walker AM; Liang C; Clifford CR; Parker C; Feldman A
Pharmacoepidemiol Drug Saf; 2014 Apr; 23(4):348-56. PubMed ID: 24375940
[TBL] [Abstract][Full Text] [Related]
38. Risk scores for contrast-induced nephropathy after percutaneous coronary intervention.
Trio O; Andò G
Int J Cardiol; 2016 Dec; 225():46. PubMed ID: 27710801
[No Abstract] [Full Text] [Related]
39. Potential mechanisms of AT1 receptor blockers on reducing pneumonia-related mortality.
Nahmod KA; Nahmod VE; Szvalb AD
Clin Infect Dis; 2013 Apr; 56(8):1193-4. PubMed ID: 23315319
[No Abstract] [Full Text] [Related]
40. Quantifying Proximal Collecting Tubule Deficiency in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Fetopathy.
Saunders J; Callejas Salgado AM; Ting JY; Mammen C; Terry J; Bush JW
Pediatr Dev Pathol; 2021; 24(5):438-444. PubMed ID: 34082612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
